CR20210618A - Composiciones y métodos para el tratamiento de las condiciones pulmonares relacionadas con biopelículas - Google Patents

Composiciones y métodos para el tratamiento de las condiciones pulmonares relacionadas con biopelículas

Info

Publication number
CR20210618A
CR20210618A CR20210618A CR20210618A CR20210618A CR 20210618 A CR20210618 A CR 20210618A CR 20210618 A CR20210618 A CR 20210618A CR 20210618 A CR20210618 A CR 20210618A CR 20210618 A CR20210618 A CR 20210618A
Authority
CR
Costa Rica
Prior art keywords
methods
compositions
related lung
lung conditions
present
Prior art date
Application number
CR20210618A
Other languages
English (en)
Inventor
Ken Alibek
Sean Farmer
Original Assignee
Locus Ip Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Locus Ip Co Llc filed Critical Locus Ip Co Llc
Publication of CR20210618A publication Critical patent/CR20210618A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/65Tetracyclines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona materiales y métodos para prevenir, inhibir o reducir la formación de biopelículas (biofilm) y las infecciones por biopelículas, en particular, en el tracto respiratorio de un sujeto. La invención utiliza subproductos del crecimiento de microorganismos beneficiosos para mejorar la eficacia de las sustancias biocidas en el tratamiento, la alteración y / o la prevención de biopelículas. Ventajosamente, la presente invención es útil contra cepas bacterianas resistentes a antibióticos, tales como MRSA (Staphylococcus aureus resistente a la meticilina), Helicobacter pylori, S. pneumoniae, P. aeruginosa y A. fumigatus.
CR20210618A 2019-05-10 2020-05-08 Composiciones y métodos para el tratamiento de las condiciones pulmonares relacionadas con biopelículas CR20210618A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962846084P 2019-05-10 2019-05-10
PCT/US2020/032039 WO2020231786A1 (en) 2019-05-10 2020-05-08 Compositions and methods for treating biofilm-related lung conditions

Publications (1)

Publication Number Publication Date
CR20210618A true CR20210618A (es) 2022-03-11

Family

ID=73046991

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210618A CR20210618A (es) 2019-05-10 2020-05-08 Composiciones y métodos para el tratamiento de las condiciones pulmonares relacionadas con biopelículas

Country Status (13)

Country Link
US (1) US11890341B2 (es)
EP (1) EP3958869A4 (es)
JP (1) JP2022531929A (es)
KR (1) KR20210154872A (es)
CN (1) CN114080236A (es)
AU (1) AU2020276206A1 (es)
BR (1) BR112021022632A2 (es)
CA (1) CA3138922A1 (es)
CR (1) CR20210618A (es)
IL (1) IL287961A (es)
MX (1) MX2021013663A (es)
SG (1) SG11202112387UA (es)
WO (1) WO2020231786A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0811530B1 (pt) 2007-05-14 2019-01-02 Research Foundation Of State Univ Of New York composição compreendendo indutor(es) de resposta fisiológica à dispersão ácido decanóico, superfície, solução, método ex vivo de tratamento ou inibição da formação de um biofilme sobre uma superfície
US20210069276A1 (en) * 2019-09-09 2021-03-11 LiquidPro Ltd. Ear spray device and ear protection composition for preventing water related ear canal disorders
US20210319900A1 (en) * 2020-04-14 2021-10-14 Siemens Healthcare Gmbh Cardiovascular assessment of patients suspected of having covid-19
US20230070870A1 (en) * 2021-09-09 2023-03-09 Robert V. West, III Covid Nasal Spray
BR102022016098A2 (pt) * 2022-08-12 2024-02-20 Universidade Estadual De Campinas Formulação antiviral e intranasal
CN115400105B (zh) * 2022-10-12 2023-08-22 湖北省农业科学院畜牧兽医研究所 焦棓酸在制备抗马链球菌兽疫亚种药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63182029A (ja) 1987-01-22 1988-07-27 Agency Of Ind Science & Technol リポソ−ム
EP0540074A1 (en) 1991-10-09 1993-05-05 ENIRICERCHE S.p.A. Cloning and sequencing of that chromosomal DNA region of bacillus subtilis comprising the SRFA operon which encodes the multienzymatic complex surfactin synthetase
JP2003246717A (ja) 2002-02-22 2003-09-02 Lion Corp 口腔用組成物
MXPA05013340A (es) 2003-06-09 2006-03-09 Nastech Pharm Co Composiciones y metodos para liberacion mucosal incrementada de la hormona del crecimiento.
AU2009205265A1 (en) 2008-01-18 2009-07-23 Hadasit Medical Research Services & Development Ltd. Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders
EP2337569A4 (en) 2008-09-25 2013-04-03 Univ New York COMPOSITIONS AND METHODS FOR CHARACTERIZING AND RESTORING THE GASTROINTESTINAL, SKIN AND NASAL MICROBIOTA
DK2424972T3 (da) 2009-04-30 2013-10-14 Actogenix Nv Kryobeskyttende midler til frysetørring af mælkesyrebakterier
US9534223B2 (en) * 2010-04-27 2017-01-03 Lysando Ag Method of reducing biofilms
MX2014009102A (es) 2012-01-27 2015-06-02 Gfs Corp Aus Pty Ltd Practicas mejoradas de granja avicola.
JP2014034552A (ja) * 2012-08-09 2014-02-24 Kao Corp バイオフィルム形成抑制剤
CN103007287A (zh) 2012-09-29 2013-04-03 湖州紫金生物科技有限公司 一种鼠李糖脂作为药物口服促吸收剂的应用
US9585903B2 (en) * 2013-09-30 2017-03-07 Council Of Scientific & Industrial Research Pharmaceutical composition comprising sophorolipid in combination with an antibiotic
WO2015153961A1 (en) * 2014-04-03 2015-10-08 Yan-Yeung Luk Synthetic disugar hydrocarbons as natural analogos to control microbial behaviors
WO2015156904A1 (en) * 2014-04-08 2015-10-15 Aradigm Corporation Liposomes that form drug nanocrystals after freeze-thaw
RU2016143590A (ru) * 2014-04-08 2018-05-11 Арадайм Корпорейшн Липосомальные композиции ципрофлоксацина, обладающие активностью против нетуберкулезных микробактерий
US20170304411A1 (en) * 2014-10-24 2017-10-26 Hprd - Health Products Research And Development Lda Topical formulation for treating skin or mucosal infections, preparation method and uses thereof
AU2017322409B2 (en) * 2016-09-08 2023-03-30 Locus Ip Company, Llc Distributed systems for the efficient production and use of microbe-based compositions

Also Published As

Publication number Publication date
AU2020276206A1 (en) 2021-12-02
MX2021013663A (es) 2022-01-24
CA3138922A1 (en) 2020-11-19
US20200353085A1 (en) 2020-11-12
EP3958869A4 (en) 2022-11-16
WO2020231786A1 (en) 2020-11-19
IL287961A (en) 2022-01-01
KR20210154872A (ko) 2021-12-21
EP3958869A1 (en) 2022-03-02
BR112021022632A2 (pt) 2022-01-04
SG11202112387UA (en) 2021-12-30
JP2022531929A (ja) 2022-07-12
US11890341B2 (en) 2024-02-06
CN114080236A (zh) 2022-02-22

Similar Documents

Publication Publication Date Title
CR20210618A (es) Composiciones y métodos para el tratamiento de las condiciones pulmonares relacionadas con biopelículas
PH12016501577A1 (en) Monobactam organic compounds for the treatment of bacterial infections
WO2016108045A3 (en) Antimicrobial compounds, compositions and methods
PH12019500360A1 (en) Antibiotic compounds
MX2019012877A (es) Prevencion, interrupcion y tratamiento de biopeliculas con lisina de bacteriofago.
WO2009126502A3 (en) Methods of inhibiting and treating biofilms using glycopeptide antibiotics
SG10201811361XA (en) Treatment of polybacterials infections
WO2018208987A3 (en) Antibacterial compounds
MX2011008043A (es) Derivados de actagardina.
WO2015100331A3 (en) Phenazine derivatives as antimicrobial agents
ZA202002093B (en) Antibacterial compounds
WO2013041663A3 (de) Modifizierte apidaecinderivate als antibiotische peptide
WO2010123599A3 (en) Anti-bacterial compositions and methods including targeting virulence factors of staphylococcus aureus
WO2015114452A3 (en) Antibacterial combinations comprising polymyxin
MX2021011147A (es) Materiales y metodos para mejorar el tratamiento y prevencion de las biopeliculas.
WO2015035234A3 (en) Anti-microbial compounds and compositions
Anyanwu Assessment of the in vitro antibacterial activity of honey on some common human pathogens
WO2009124086A3 (en) Antibacterial drug for treatment of staphylococcus aureus and other gram-positive bacterial infections
EA201892278A1 (ru) Анбитактериальные биароматические производные с оксетан-3-илокси замещением
Gomes et al. Antimicrobial activity of phenolic extracts of Eucalyptus globulus and Juglans regia against dairy industry pathogens
WO2010131865A3 (ko) 항생제 내성 균주에 대한 항균용 조성물
EA201700519A2 (ru) АНТИМИКРОБНАЯ КОМБИНАЦИЯ В ОТНОШЕНИИ УСТОЙЧИВЫХ К КАРБАПЕНЕМАМ ГРАМОТРИЦАТЕЛЬНЫХ БАКТЕРИЙ ВИДА KLEBSIELLA PNEUMONIAE, ПРОДУЦИРУЮЩИХ МЕТАЛЛО-β-ЛАКТАМАЗУ
MX2014013637A (es) Metodos para prevencion de la formacion de biopelicula.
TW202417432A (zh) 抗菌化合物
TW202417437A (zh) 抗菌化合物